World-leading capabilities in multiplexable gene editing
Join Our Team
Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Newsroom
Press Releases
Dr. Luhan Yang Selected for the Inaugural Aspen Institute Technology Leaders Initiative2026/07/17
Qihan Biotech today announced that its Co-Founder and Chief Executive Officer, Dr. Luhan Yang, has been selected for the Technology Leaders Initiative (TLI) of the Aspen Institute. Dr. Yang is one of 22 leaders chosen for the initiative’s inaugural global cohort.
1 / 3Press Releases
Qihan Biotech's QT-019B Receives FDA RMAT and BTD2026/06/11
Qihan Biotech announced that its internally developed universal dual-target CAR-T therapy, QT-019B, has officially received both Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough Therapy Designation (BTD) from the U.S. FDA.
1 / 3Press Releases
Qihan Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially optimized low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases2026/05/15
Qihan Biotech announced today that QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
1 / 3
Contact Us
Hangzhou Qihan Biotech Co., Ltd.
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311200
TEL: 0571-83500380
FAX: 0571-83500370